Stevens-Johnson Syndrome Induced by Carbamazepine  
Treatment in a Patient Who Previously Had Carbamazepine Induced Pruritus  
- A Case Report -  

Hyun Min Bae, MD, Yoo Jung Park, MD, Young Hoon Kim, MD, and Dong Eon Moon, MD

Stevens-Johnson Syndrome (SJS) is a rare but life-threatening skin reaction disease and carbamazepine is one of its most common causes. We report a case of SJS secondary to carbamazepine in a patient with previous pruritus due to carbamazepine which was given for treatment of trigeminal neuralgia. We would like to caution all providers that carbamazepine readministration should be avoided in the patient with a previous history of SJS or adverse skin reaction. In addition, we strongly recommend gradual titration when initiating treatment with carbamazepine. (Korean J Pain 2013; 26: 80-83)

Key Words:  
carbamazepine, drug hypersensitivity reaction, Stevens-Johnson syndrome, trigeminal neuralgia.
Carbamazepine hypersensitivity reaction is between 1/1,000 and 1/10,000 new exposures to the drug [5]. The reported frequency of serious carbamazepine hypersensitivity reaction is between 1/1,000 and 1/10,000 new exposures to the drug [5].

The object of this article was to report a case of SJS secondary to carbamazepine in a patient with trigeminal neuralgia.

**CASE REPORT**

A 68-year-old male presented with left mandibular area pain due to third trigeminal neuralgia. He had undergone conventional radiofrequency lesioning in the left third branch of the trigeminal nerve for trigeminal neuralgia one year previously. Following the procedure, he had been without pain until quite recently. However, at the time of his presentation, he was reporting pain in the same area of 40/100 using the VAS (Visual Analogue Scale) score. We decided to proceed with medical treatment including carbamazepine 200 mg three times a day, tramadol (37.5 mg)/acetaminophen (325 mg) combination three times a day, and nortriptyline 10 mg one time a day because his pain was mild. On his second day of medication, a mild fever and general weakness had occurred. On his fourth day after beginning the medication, an oral rash and bullae on the cheek, neck, forearm, and leg were found. On the fifth day, the patient visited the emergency room and was admitted with a presumptive diagnosis of SJS. Further history revealed that he had discontinued medication including carbamazepine 200 mg one year previously on his own due to pruritus after taking the medication once. The medical history was otherwise unremarkable. On physical examination, the patient displayed pruritic and stinging erythema and painful crusted erosions on both lips, with several flaccid and ruptured bullae on the left cheek, neck, forearm, and leg (Fig. 1). Pharyngitis was present but he was able to swallow some food. Eye discomfort and genital mucosa involvement were not present. Nikolsky’s sign was positive. Laboratory examination revealed mild leukocytosis, and alanine aminotransferase, C-reactive protein, and potassium were mildly elevated. Carbamazepine was withdrawn and prednisolone 125 mg/day was started. A skin biopsy performed on the third day after admission, demonstrated subepidermal bullae formation with epidermal necrosis and minimal perivascular lymphohistocytic infiltration in the upper dermis and the correct diagnosis of SJS was established. Steroid treatment was given for 5 days and gradually withdrawn. On the eighth day the patient was discharged in good condition, with generalized desquamation and incomplete peeling of the skin on the neck, forearm, and face. Two weeks after discharge, he underwent conventional radiofrequency lesioning of the left third branch of the trigeminal nerve. Two weeks later, his pain was nearly gone.

**DISCUSSION**

Trigeminal neuralgia involves severe, lancinating pain, triggered by non-nociceptive stimuli, in the distribution of one or more divisions of the trigeminal nerve. The primary medications used to treat the painful symptoms of trigeminal neuralgia are anticonvulsants. The first-line treatment is carbamazepine [6].

Carbamazepine has been strongly associated with SJS. Although SJS has multiple etiologies, it is commonly triggered by viral infections (herpes simplex virus is the infectious agent more commonly involved) and neoplasias.

**Fig. 1.** Skin and mucosa of our patient: ruptured bullae over the right arm and oral mucosa were involved by SJS.
Glucocorticoids have not been proven useful in SJS. They are not indicated as part of the treatment for acute SJS other than supportive care. The mechanism by which SJS develops is not well understood. SJS usually occurs during the first course of drug ingestion (without prior sensitization). T-cells are already present in the body before drug exposure and elicit a robust immune reaction on carbamazepine antigenic stimulation.

At present, the mechanisms by which SJS develops are not well understood. SJS usually occurs during the first course of drug ingestion (without prior sensitization). T-cells are already present in the body before drug exposure and elicit a robust immune reaction on carbamazepine antigenic stimulation.

Typically, the initial presentation is marked by symptoms of fever, myalgia, and general weakness for 1 to 3 days before the development of cutaneous lesions. The skin lesions are symmetrically distributed on the face and upper trunk areas. The rash spreads rapidly and is usually maximal within four days, sometimes within hours. The initial skin lesions are usually poorly defined macules with darker purpuric centers that coalesce.

Diagnosis is clinical. However, skin biopsy helps confirm the diagnosis, usually excluding bullous diseases not related to drug therapy. Early on, there is full-thickness epidermal necrosis and detachment, with an only slightly altered underlying dermis. Immunofluorescence studies only help exclude other bullous disease. Anemia and lymphopenia are frequent, but eosinophilia is rare. Neutropenia suggests a poor prognosis.

The main therapeutic action in SJS is early recognition of the drug reaction and withdrawal of the drug, since any delay can be seriously deleterious to the patient. There is no universally accepted, definitively effective, specific treatment for acute SJS other than supportive care. Glucocorticoids have not been proven useful in SJS. They may be beneficial in the early stage of SJS but may increase the risk of infection, prolong wound healing, or even increase mortality, if bullous eruption or mucosal erosion is fully developed. Although some retrospective studies have suggested that intravenous immunoglobulin may be effective in stopping the progression of SJS, other studies showed limited benefit on the mortality rate or progression of the disease.

The patient in this case was given the same drug (carbamazepine) twice, but the degree of his cutaneous reaction was greater with the second exposure, when he developed SJS. On his first exposure to the medication, he took one dose of carbamazepine 200 mg. The second time, he took carbamazepine 600 mg a day for 5 days. We assumed that SJS did not occur on the first administration of carbamazepine because the patient stopped taking the medication after a single dose, which is not enough dosage to trigger hypersensitivity reaction. Huang et al. also reported a case of fetal toxic epidermal necrolysis induced by carbamazepine treatment in a patient who previously had carbamazepine-induced SJS. It has been reported that higher daily doses of some drugs are associated with an increased risk of SJS compared to lower doses, as is the case for allopurinol. However, there is as yet no evidence about the relationship between carbamazepine dosage and SJS.

It is important to note that carbamazepine readministration should be avoided in patients with a previous history of SJS or adverse skin reaction to carbamazepine through the obtaining of an accurate medical history. In addition we advise a gradual titration at the start of treatment with anticonvulsant.

REFERENCES

1. Auquier-Dunant A, Mockenhaupt M, Naidi L, Correia D, Schröder W, Roujeau JC, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138: 1019–24.

2. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64: 1134–8.

3. Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, et al. Apoptosis as a mechanism of keratinocyte...
death in toxic epidermal necrolysis, Br J Dermatol 1996: 134: 710–4.
4. Leeder JS. Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs, Epilepsia 1998: 39 Suppl 7: S8–16.
5. Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study, Neurology 1997: 49: 542–6.
6. Larsen A, Piepgras D, Chyatte D, Rizzolo D. Trigeminal neuralgia: diagnosis and medical and surgical management, JAAPA 2011: 24: 20–5.
7. Lefko E, Papaliodis DN, Papaliodis GN, Daoud YJ, Ahmed AR, Foster CS. Stevens–Johnson syndrome and toxic epidermal necrolysis: a review of the literature, Ann Allergy Asthma Immunol 2005: 94: 419–36.
8. Devi K, George S, Criton S, Suja V, Sridevi PK. Carbamazepine—-the commonest cause of toxic epidermal necrolysis and Stevens–Johnson syndrome: a study of 7 years, Indian J Dermatol Venereol Leprol 2005: 71: 325–8.
9. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, et al. Stevens–Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs, The EuroSCAR study, J Invest Dermatol 2008: 128: 35–44.
10. Wu Y, Sanderson JP, Farrell J, Drummond NS, Hanson A, Bowkett E, et al. Activation of T cells by carbamazepine and carbamazepine metabolites, J Allergy Clin Immunol 2006: 118: 233–41.
11. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs, N Engl J Med 1994: 331: 1272–85.
12. Huang LY, Liao WC, Chiou CC, Lou JP, Hu P, Ko FC. Fatal toxic epidermal necrolysis induced by carbamazepine treatment in a patient who previously had carbamazepine-induced Stevens–Johnson syndrome, J Formos Med Assoc 2007: 106: 1032–7.
13. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens–Johnson syndrome and toxic epidermal necrolysis in Europe and Israel, J Am Acad Dermatol 2008: 58: 25–32.